Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 2/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 11/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL597167 | 0.84 | CYP2B6 (0.52) | OPRM1MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL8013935 | 0.84 | CYP2B6 (0.52) | OPRM1MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL2816539 | 0.83 | KCNA5 (0.46) | KCNA5OPRM1OPRD1SMN1; SMN2MEN1 | |
| Hydrochloric Acid SCHEMBL8017738 | 0.83 | CYP2B6 (0.50) | OPRM1MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL7547849 | 0.83 | CYP2B6 (0.55) | OPRM1MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL9816209 | 0.80 | CHRM2 (0.48) | KCNA5OPRM1OPRD1SMN1; SMN2MEN1 | |
| SCHEMBL11541847 | 0.77 | SMN1; SMN2 (0.54) | KCNA5OPRM1OPRD1SMN1; SMN2MEN1 | |
| SCHEMBL28845914 | 0.75 | SMN1; SMN2 (0.49) | KCNA5OPRM1OPRD1SMN1; SMN2MEN1 | |
| SCHEMBL18901958 | 0.73 | OPRM1 (0.44) | KCNA5OPRM1OPRD1SMN1; SMN2MEN1 | |
| SCHEMBL18889556 | 0.73 | OPRM1 (0.60) | KCNA5OPRM1OPRD1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622486-B2 | Pyridine compounds, process for their preparation and compositions containing them | REDDY US THERAPEUTICS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20060084644-A1 | Novel pyridine compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084644-A1 | Novel pyridine compounds, process for their preparation and compositions containing them | LDLR, LRP6, PLPBP | KCNA5 2953/4885OPRM1 3531/4885OPRD1 4295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.